May. 6 at 10:53 AM
$OMCL Omnicell reports Q1 non-GAAP EPS 26c, consensus 20c
Reports Q1 revenue
$270M, consensus
$259.97M. "We delivered strong financial results for the Q1, exceeding our previously provided guidance ranges for both revenue and earnings, which we believe reflects customers embracing the industry-defined vision of the Autonomous Pharmacy including medication management solutions across the continuum of care," stated Randall Lipps, chairman, president, CEO, and founder of Omnicell.
"While uncertainty surrounding the potential impact of tariffs has compelled us to update our full-year outlook, our focus on driving annual recurring revenue services and recurring revenue is expected to serve us well as we implement strategies that are designed to mitigate the potential impact of tariffs on our supply chain. Importantly, our balance sheet remains strong, with solid free cash flow, which should help us remain nimble and capable of navigating the current macroeconomic environment while continuing to offer market-leading innovation and execution that our customers have come to expect."
